Claims
- 1. A method for treating an ophthalmological disorder, said method comprising the step of:
A. contacting with the vitreous body of an eye of the patient a therapeutic amount of a compound selected from the group consisting of:
urea; urea derivatives; thiourea; thiourea derivatives; guanidine; guanidine derivatives; and, compounds having the general formula: 4Wherein: R is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, C1l-C6 alkylphenyl or hydroxyl protecting group; R1 and R2 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalky, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkenyl, —S(O)q(C1-C6 alkenyl) or 5Wherein A is —CH2—, —O—, —S—, —S(O)— or —S(O)2—: W1 and W2 are each independently hydrogen, halo, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy,, C1-C4 alkylthio,, C2-C4 alkenyl, or, C2-C4 alkynyl; R3 is hydrogen,, C1-C8 alkyl,, C3-C8 cycloalkyl, or, C1-C6 alkylphenyl; X is O, S, or NR4; R4 is hydrogen,, C1-C6 alkyl,, C1-C4 alkylphenyl or, C1-C6 alkoxy; R5 is hydrogen,, C3-C8 cycloalkyl or C1-C8 alkyl; 6Wherein Z1 and Z2 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, hydroxyl, C2-C4 alkenyl, C2-C6 alkyl, C1-C6alkythio, halo, trifluoromethyl or —NR6R7; R6 and R7 are each independently hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C4 alkylphenyl; n is 1 to 6 all inclusive; m and p are each independently 0 to 6, both inclusive; q is 0, 1 or 2; and pharmaceutical salts thereof.
- 2. A method according to claim 1 wherein the compound is injected intravitreally.
- 3. A method according to claim 1 wherein the method is carried out to treat a retinal tear.
- 4. A method according to claim 3 further comprising the step of:
B performing a retinopexy procedure after administration of the compound in Step A.
- 5. A method according to claim 4 wherein Step B is performed approximately 3 days after Step A.
- 6. A method according to claim 1 wherein the method is carried out to cause vitreal liquefaction and collapse.
- 7. A method according to claim 1 wherein the method is carried out to cause posterior vitreo-retinal detachment and collapse.
- 8. A method according to claim 1 wherein the method is carried out to treat a macular hole.
- 9. A method according to claim 1 wherein the method is carried out to treat vitreous hemorrhage.
- 10. A method according to claim 9 wherein the method is carried out to accelerate the clearance of hemorrhagic blood from the vitreous humor.
- 11. A method according to claim 1 wherein the method is carried out as an adjunct to virectomy.
- 12. A method according to claim 11 further comprising the step of:
B. performing a vitrectomy after performance of Step A.
- 13. A method according to claim 12 wherein Step B is carried out at least 1 day after Step A.
- 14. A method according to claim 1 wherein the method is carried out to treat macular edema.
- 15. A method according to claim 1 wherein the method is carried out to treat optic nerve damage.
- 16. A method according to claim 1 wherein the method is carried out to treat optic neuropathy.
- 17. A method according to claim 1 wherein the method is carried out to treat rubeosis.
- 18. A method according to claim 1 wherein the method is carried out to treat neovascular glaucoma.
- 19. A method according to claim 1 wherein the method is carried out to treat diabetic retinopathy.
- 20. A method according to claim 1 further comprising the step of:
B. contacting with the vitreous humor a therapeutic amount of a nonsteroidal antiinflamatory agent.
- 21. A method according to claim 20 wherein Steps A and B are carried out concurrently by administering a solution containing a compound according to claim 1 in combination with an nonsteroidal antiinflamatory agent.
- 22. A method for preventing or treating a disorder of a nerve, said method comprising the step of:
A. contacting with the nerve a therapeutically effective amount of a compound selected from the group consisting of:
urea; urea derivatives; thiourea; thiourea derivatives; guanidine; guanidine derivatives; and, compounds having the general formula: 7Wherein: R is hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C6 alkylphenyl or hydroxyl protecting group; R1 and R2 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalky, C2-C6 alkynyl, C1-C6 alkoxy, C2-C6alkenyl, C2-C6 alkenyl, —S(O)q(C1-C6 alkenyl) or 8Wherein A is —CH2—, —O—, —S—, —S(O)— or —S(O)2—: W1 and W2 are each independently hydrogen, halo, hydroxyl, C1-C4 alkyl, C1-C4 alkoxy,, C1-C4 alkylthio,, C2-C4 alkenyl, or, C2-C4 alkynyl; R3 is hydrogen,, C1-C8alkyl,, C3-C8cycloalkyl, or, C1-C6alkylphenyl; X is O, S, or NR4; R4 is hydrogen,, C1-C6 alkyl,, C1-C4alkylphenyl or, C1-C6 alkoxy; R5 is hydrogen,, C3-C8 cycloalkyl or C1-C8 alkyl; Y is 9Wherein Z1 and Z2 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, hydroxyl, C2-C4 alkenyl, C2-C6 alkyl, C1-C6alkythio, halo, trifluoromethyl or —NR6R7; R6 and R7 are each independently hydrogen, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C4 alkylphenyl; n is 1 to 6 all inclusive; m and p are each independently 0 to 6, both inclusive; q is 0, 1 or 2; and pharmaceutical salts thereof.
- 23. A method according to claim 22 wherein the method is carried out for the purpose of treating a disorder of the optic nerve.
- 24. A method according to claim 23 wherein the compound is delivered in Step A by intravitreal injection.
- 25. A method according to claim 22 wherein the method is carried out to treat a disorder of the spinal chord or brain.
- 26. A method according to claim 25 wherein the compound is delivered in Step A by intrathecal injection.
- 27. A method according to claim 22 wherein the method is carried out to treat a disorder of a peripheral nerve.
- 28. A method according to claim 27 wherein the compound is delivered in Step A by injection into or adjacent to the peripheral nerve.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Serial No. 60/357,347, filed Feb. 13, 2002, and U.S. Provisional Application Serial No. 60/357,574, filed Feb. 15, 2002. This application is also a continuation-in-part application of U.S. application Ser. No. 10/215,680, filed Aug. 9, 2002, which is a continuation application of U.S. application Ser. No. 09/517,798, filed Mar. 2, 2000, now U.S. Pat. No. 6,462,071. The contents of all the foregoing patent applications are hereby incorporated by reference in their entireties.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60357347 |
Feb 2002 |
US |
|
60357574 |
Feb 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09517798 |
Mar 2000 |
US |
Child |
10367614 |
Feb 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10215680 |
Aug 2002 |
US |
Child |
10367614 |
Feb 2003 |
US |